ERAS, US29479A1088

Erasca stock: BMS to test ERAS-0015 in pancreatic cancer trial

Published on 11/19/2026 at 02:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Erasca stock is in focus after Bristol Myers Squibb agreed to test ERAS-0015 in a Phase 1/2 study. Erasca will supply the drug for MTAP-deleted pancreatic cancer.

Clinical partnership expands Erasca pipeline

  • Bristol Myers Squibb will sponsor a Phase 1/2 trial combining navlimetostat with ERAS-0015.
  • The study will target patients with MTAP-deleted pancreatic ductal adenocarcinoma.
  • Erasca is also advancing ERAS-0015 in the AURORAS-1 Phase 1 trial.
ERAS, US29479A1088, Illustration mit AI erstellt.

Erasca said on November 17, 2026, that it had entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate ERAS-0015 with navlimetostat in MTAP-deleted pancreatic ductal adenocarcinoma. The company announced the agreement in a Erasca release.

BMS takes the lead on trial

Bristol Myers Squibb will sponsor the Phase 1/2 study, while Erasca will supply ERAS-0015. The companies will retain development and commercial rights to their respective compounds, and the agreement is mutually non-exclusive.

The trial will combine Erasca's investigational oral pan-RAS molecular glue with navlimetostat, an investigational PRMT5 inhibitor from Bristol Myers Squibb. The companies are targeting MTAP-deleted pancreatic tumors, a setting in which the release says nearly all tumors carry co-occurring RAS mutations.

Pipeline timing remains central

Erasca is evaluating ERAS-0015 in the AURORAS-1 Phase 1 trial for patients with RAS-mutant solid tumors. The company reported early dose-escalation activity across several tumor types and said confirmed partial responses had been observed at doses as low as 8 milligrams once daily. Those findings remain clinical-stage data and will require further follow-up.

The collaboration comes as Erasca presents updated ERAS-0015 data at the EORTC-NCI-AACR Symposium in Barcelona from November 18 through November 20. Erasca also plans a virtual investor event on November 20 to discuss the updated Phase 1 data and other pipeline developments.

Erasca's oncology focus

Erasca is a clinical-stage precision oncology company based in San Diego, California. It discovers, develops and commercializes therapies for cancers driven by the RAS and MAPK pathways, using small molecules, larger molecules and protein degraders across single-agent and combination programs. Its pipeline is designed to address multiple signaling nodes and escape routes across several tumor types.

Erasca company profile

  • Company: Erasca, Inc.
  • Ticker: ERAS
  • Headquarters: San Diego, California
  • Focus: Precision oncology for RAS- and MAPK pathway-driven cancers

The broader US market environment can be followed through the S&P 500.

More news and analyses on Erasca stock are available in the company coverage.

Disclaimer...
en | US29479A1088 | ERAS | boerse | 70533333 | bgmi